<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04111952</url>
  </required_header>
  <id_info>
    <org_study_id>0349-19-RMB</org_study_id>
    <nct_id>NCT04111952</nct_id>
  </id_info>
  <brief_title>The Effect of Additional Laser Treatments.</brief_title>
  <official_title>The Efficacy and Safety of an Additional Vaginal Laser Treatment in Women Previously Treated With Laser for Gynecological Indications.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rambam Health Care Campus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rambam Health Care Campus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Women previously treated with vaginal CO2 laser will receive an additional treatment 6 months&#xD;
      after cessation of previous laser treatment or a sham laser treatment. The efficacy and&#xD;
      safety of the additional treatment will be assessed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The following study is intended to evaluate the efficacy and safety of an additional laser&#xD;
      treatment for women previously treated for gynecological indications with laser treatments.&#xD;
      Women will be randomized to one of 2 groups: 1. Study group-additional single laser&#xD;
      treatment. 2. Control group-single sham laser treatment. All women will fill out validated&#xD;
      questionnaires regarding sexual function, urinary stress incontinence and satisfaction after&#xD;
      treatment. All women will be followed for an additional 6 months to evaluate the length of&#xD;
      effect.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Length of effect</measure>
    <time_frame>From the treatment session up to 6 months post-treatment</time_frame>
    <description>The duration of symptom improvement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Female sexual function index</measure>
    <time_frame>From the treatment session up to 6 months post-treatment</time_frame>
    <description>Changes in the female sexual function index questionnaire score (range 0-35)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sexual intercourse</measure>
    <time_frame>From the treatment session up to 6 months post-treatment</time_frame>
    <description>Improvement in the monthly rate of sexual intercourse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary distress index</measure>
    <time_frame>From the treatment session up to 6 months post-treatment</time_frame>
    <description>Changes in the urinary distress index questionnaire score (range 0-15)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">170</enrollment>
  <condition>Lax Vaginal Introitus</condition>
  <arm_group>
    <arm_group_label>Additional laser treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women receiving a single laser treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham laser treatment</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Women receiving sham laser treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CO2 laser</intervention_name>
    <description>A single session of CO2 vaginal laser treatment</description>
    <arm_group_label>Additional laser treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham laser</intervention_name>
    <description>A single session of sham laser treatment.</description>
    <arm_group_label>Sham laser treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Previously treated with 3 laser treatments.&#xD;
&#xD;
          -  Clear PAP test from the last 3 years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Vaginal bleeding of unknown source.&#xD;
&#xD;
          -  Vaginal surgery in the past 9 months.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roy Lauterbach, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rambam Health Care Campus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rambam health care campus</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 30, 2019</study_first_submitted>
  <study_first_submitted_qc>September 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 2, 2019</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rambam Health Care Campus</investigator_affiliation>
    <investigator_full_name>ROY LAUTERBACH MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

